pre-IPO PHARMA

COMPANY OVERVIEW

Apic Bio is committed to finding cures for patients with genetic diseases. The company is a spin-off from the University of Massachusetts Medical School (UMMS) and is based upon nearly 30 years of gene therapy research by Apic’s scientific founders. Apic is developing best-in-class treatment options for rare, devastating neurological and liver diseases.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Liver Disease
  • Neurodegenerative Disease
  • Rare Diseases

  • WEBSITE

    https://www.apic-bio.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    a1atd-investors als-investment-fund morningside-technology-advisory the-alpha-1-project


    PRESS RELEASES


    Jul 28, 2021

    Apic Bio Receives FDA Fast Track Designation for APB-102 for the Treatment of Patients with SOD1 ALS


    Apr 21, 2021

    Apic Bio Announces FDA Clearance of IND Application for Lead Gene Therapy Candidate APB-102 for the Treatment of SOD1 ALS


    Jan 5, 2021

    Apic Bio Announces the Appointment of Stephen Hoffman, MD, PhD, as Board Chair


    Aug 26, 2020

    Apic Bio Announces Appointment of Jorge A. Quiroz, MD, MBA, as Executive Vice President and Chief Medical Officer


    Jul 27, 2020

    Apic Bio Announces Formation of Scientific Advisory Board


    For More Press Releases


    Google Analytics Alternative